Leading all biotech initial public offerings conducted this year in the U.S., Coley Pharmaceutical Group Inc. topped the list with proceeds of $96 million, then raised another $10 million through a concurrent private placement with Pfizer Inc.(BioWorld Today)

Two months ago, when Anadys Pharmaceuticals Inc. signed what might be the largest Phase I deal in biotech history, the company's CEO said Anadys wouldn't need to do a financing for at least two years. (BioWorld Today)

Inching closer to a market that, until recently, was virtually untapped, XenoPort Inc. proved in a Phase IIb trial that its restless leg syndrome candidate, XP13512, was significantly better than placebo in relieving patient symptoms. (Bioworld Today)

In order to grow in the area of proteomics, Invitrogen Corp. signed a definitive agreement to acquire BioSource International Inc. for about $130 million in cash. (BioWorld Today)